Journal Mobile Options
Table of Contents
Vol. 141, No. 1, 2006
Issue release date: August 2006
Int Arch Allergy Immunol 2006;141:11–23

Investigations on the Involvement of the Lectin Pathway of Complement Activation in Anaphylaxis

Windbichler M. · Echtenacher B. · Takahashi K. · Ezekowitz R.A.B. · Schwaeble W.J. · Jenseniuis J.C. · Männel D.N.
aInstitute of Immunology, University of Regensburg, Regensburg, Germany; bDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK; cDepartment of Pediatrics, Laboratory of Developmental Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass., USA; dDepartment of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Systemic anaphylaxis is the most severe form of immediate hypersensitivity reaction. The activation of the complement system occurs during anaphylactic shock. The purpose of this study was to determine in a mouse model whether the lectin pathway of complement activation is involved in anaphylaxis. Methods: To see whether the lectin pathway is involved in anaphylactic shock, serum mannan-binding lectin (MBL) levels were measured after passive anaphylaxis. Also MBL expression and binding to potential ligands were investigated. To determine whether complement or mast cell activation is essential for hypothermia in anaphylactic shock, mouse strains deficient in MBL-A and MBL-C, C1q, factors B and C2, C5, C5aR, or mast cells were tested. Results: After antigenic challenge a marked drop in body temperature as well as a rapid decrease in serum MBL levels were observed. The decrease of serum MBL levels in shock could not be attributed to MBL binding to immune complexes or tissues, but an interaction of MBL with mast cell-derived proteoglycans was seen. In contrast to mast cell-deficient mice, none of the complement-deficient mouse strains were protected from shock-associated hypothermia. Conclusions: These results indicate that neither MBL nor activation of the complement cascade is crucial for the induction of anaphylaxis. In contrast mast cell activation is associated with the development of hypothermia and possibly the observed decrease in serum MBL levels.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kemp SF, Lockey RF: Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002;110:341–348.
  2. Lei HY, Lee SH, Leir SH: Antigen-induced anaphylactic death in mice. Int Arch Allergy Immunol 1996;109:407–412.
  3. Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Drazen JM, Leder P: Active anaphylaxis in IgE-deficient mice. Nature 1994;370:367–370.
  4. Nagata S, Glovsky MM: Activation of human serum complement with allergens. I. Generation of C3a, C4a, and C5a and induction of human neutrophil aggregation. J Allergy Clin Immunol 1987;80:24–32.
  5. Del Balzo U, Polley MJ, Levi R: Activation of the third complement component (C3) and C3a generation in cardiac anaphylaxis: histamine release and associated inotropic and chronotropic effects. J Pharmacol Exp Ther 1988;246:911–916.
  6. Van der Linden PW, Hack CE, Kerckhaert JA, Struyvenberg A, van der Zwan JC: Preliminary report: complement activation in wasp-sting anaphylaxis. Lancet 1990;336:904–906.
  7. Regal JF, Fraser DG, Toth CA: Role of the complement system in antigen-induced bronchoconstriction and changes in blood pressure in the guinea pig. J Pharmacol Exp Ther 1993;267:979–988.
  8. Holmskov U, Thiel S, Jensenius JC: Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003;21:547–578.
  9. Schwaeble WJ, Reid KB: Does properdin crosslink the cellular and the humoral immune response? Immunol Today 1999;20:17–21.
  10. Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H: Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 2003;162:449–455.
  11. Tannenbaum H, Ruddy S, Schur PH: Acute anaphylaxis associated with serum complement depletion. J Allergy Clin Immunol 1975;56:226–234.
  12. Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56–59.
  13. Taylor PR, Nash JT, Theodoridis E, Bygrave AE, Walport MJ, Botto M: A Targeted disruption of the murine complement factor B gene resulting in loss of expression of three genes in close proximity, factor B, C2, and D17H6S45. J Biol Chem 1998;273:1699–1704.
  14. Shi L, Takahashi K, Dundee J, Shahroor-Karni S, Thiel S, Jensenius JC, Gad F, Hamblin MR, Sastry KN, Ezekowitz RA: Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med 2004;199:1379–1390.
  15. Hopken UE, Lu B, Gerard NP, Gerard C: The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996;383:86–89.
  16. Makabe-Kobayashi Y, Hori Y, Adachi T, Ishigaki-Suzuki S, Kikuchi Y, Kagaya Y, Shirato K, Nagy A, Ujike A, Takai T, Watanabe T, Ohtsu H: The control effect of histamine on body temperature and respiratory function in IgE-dependent systemic anaphylaxis. J Allergy Clin Immunol 2002;110:298–303.
  17. Petersen SV, Thiel S, Jensen L, Steffensen R, Jensenius JC: An assay for the mannan-binding lectin pathway of complement activation. J Immunol Methods 2001;257:107–116.
  18. Dodds AW: Small-scale preparation of complement components C3 and C4. Methods Enzymol 1993;223:46–61.
  19. Liu H, Jensen L, Hansen S, Petersen SV, Takahashi K, Ezekowitz AB, Hansen FD, Jensenius JC, Thiel S: Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. Scand J Immunol 2001;53:489–497.
  20. Thiel S, Moller-Kristensen M, Jensen L, Jensenius JC: Assays for the functional activity of the mannan-binding lectin pathway of complement activation. Immunobiology 2002;205:446–454.
  21. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB: Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995;1:237–243.
  22. Roos A, Bouwman LH, Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha R: Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001;167:2861–2868.
  23. Celik I, Stover C, Botto M, Thiel S, Tzima S, Kunkel D, Walport M, Lorenz W, Schwaeble W: Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis. Infect Immun 2001;69:7304–7309.
  24. Van den Berg CW, Hofhuis FM, Rademaker PM, van Dijk H: Induction of active immunological hypo/non-responsiveness to C5 in adult C5-deficient DBA/2 mice. Immunology 1991;74:380–385.
  25. Arnold JN, Radcliffe CM, Wormald MR, Royle L, Harvey DJ, Crispin M, Dwek RA, Sim RB, Rudd PM: The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin. J Immunol 2004;173:6831–6840.
  26. Windbichler M, Echtenacher B, Hehlgans T, Jensenius JC, Schwaeble W, Mannel DN: Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis. Infect Immun 2004;72:5247–5252.
  27. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL: Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001;159:1045–1054.
  28. De Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA: The mannose-binding lectin pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004;165:1677–1688.
  29. Uemura K, Saka M, Nakagawa T, Kawasaki N, Thiel S, Jensenius JC, Kawasaki T: L-MBP is expressed in epithelial cells of mouse small intestine. J Immunol 2002;169:6945–6950.
  30. Ueki A, Sai T, Oka H, Tabata M, Hosokawa K, Mochizuki Y: Biosynthesis and secretion of the third component of complement by human endothelial cells in vitro. Immunology 1987;61:11–14.
  31. Strunk RC, Eidlen DM, Mason RJ: Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988;81:1419–1426.
  32. Andoh A, Fujiyama Y, Bamba T, Hosoda S: Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2. J Immunol 1993;151:4239–4247.
  33. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM: Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003;170:1517–1523.
  34. Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF: Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol 1983;130:1891–1895.
  35. Ward PA, Hill JH: C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol 1970;104:535–543.
  36. Johnson AR, Hugli TE, Muller-Eberhard HJ: Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 1975;28:1067.
  37. Frank MM, Fries LF: The role of complement in inflammation and phagocytosis. Immunol Today 1991;12:322–326.
  38. Okunuki H, Teshima R, Sakushima J, Akiyama H, Goda Y, Toyoda M, Sawada JI: Induction of active systemic anaphylaxis by oral sensitization with ovalbumin in mast cell-deficient mice. Immunol Lett 2000;74:233–237.
  39. Martin TR, Galli SJ, Katona IM, Drazen JM: Role of mast cells in anaphylaxis: evidence for the importance of mast cells in the cardiopulmonary alterations and death induced by anti-IgE in mice. J Clin Invest 1989;83:1375–1383.
  40. Serafin WE, Austen KF: Mediators of immediate hypersensitivity reactions. N Engl J Med 1987;317:30–34.
  41. Dombrowicz D, Flamand V, Miyajima I, Ravetch JV, Galli SJ, Kinet JP: Absence of Fc epsilonRI alpha chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis: evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR beta and gamma chains. J Clin Invest 1997;99:915–925.
  42. Razin E, Stevens RL, Akiyama F, Schmid K, Austen KF: Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J Biol Chem 1982;257:7229–7236.
  43. Yurt RW, Leid RW Jr, Austen KF: Native heparin from rat peritoneal mast cells. J Biol Chem 1977;252:518–521.
  44. Almeda S, Rosenberg RD, Bing DH: The binding properties of human complement component C1q: interaction with mucopolysaccharides. J Biol Chem 1983;258:785–791.
  45. Sahu A, Pangburn MK: Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 1993;30:679–684.
  46. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP: Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992;148:3210–3215.
  47. Presanis JS, Hajela K, Ambrus G, Gal P, Sim RB: Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 2004;40:921–929.
  48. Monge JC, Recondo EF, Fernandez de Recondo ME: Heparin and concanavalin A interaction as a model for studying the mechanism of the anticoagulant activity. Thromb Res 1989;54:237–243.
  49. Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF: Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981;67:223–228.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50